- Home
- ITOS
as 12-24-2024 4:00pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 271.1M | IPO Year: | 2020 |
| Target Price: | $21.33 | AVG Volume (30 days): | 519.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.09 - $18.75 | Next Earning Date: | 11-12-2024 |
| Revenue: | $35,000,000 | Revenue Growth: | -47.37% |
| Revenue Growth (this year): | 271.18% | Revenue Growth (next year): | -85.39% |
Stock Insider Trading Activity of iTeos Therapeutics Inc. (ITOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gall Matthew | ITOS | Chief Financial Officer | Nov 19 '24 | Buy | $7.73 | 5,000 | $38,635.00 | 65,429 |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
TipRanks
6 days ago
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo
Clinical Trials Arena
13 days ago
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy
MT Newswires
14 days ago
iTeos Therapeutics Says Deprioritizing Cancer Drug Candidate Inupadenant
GlobeNewswire
14 days ago
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
GlobeNewswire
a month ago
iTeos to Participate in Upcoming Investor Conferences
Simply Wall St.
a month ago
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
GlobeNewswire
a month ago
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
2 months ago
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.